Skip to main content
. 2021 May;13(5):2716–2727. doi: 10.21037/jtd-20-3525

Figure 1.

Figure 1

Kaplan-Meier analysis of OS (A) and PFS (B), ORR (C) and DCR (D) for patients with advanced NSCLC receiving IO according to the presence or absence of peripheral blood eosinophilia during treatment. OS, overall survival; PFS, progression-free survival; ORR, overall response rate; DCR, disease control rate; NSCLC, non-small cell lung cancer; IO, immunotherapy.